NFE2L2 and prostate cancer: Furthermore, demethylated CpGs in NFE2L2 promoter region on account of decreased HDACs synergistically accompanied with attenuated DNMTs after treatment with DIM in prostate cancer (Lewinska et al., 2017) or Delphinidin in the mouse skin JB6 P+ cells (Kuo et al., 2019) was observed, contributing to enhanced expression of NRF2 and its downstream target gene such as HMOX1, NQO1 and SOD1, ultimately inducing different anticancer effects such as the upregulated detoxification and excretion of chemicals (Nioi and Hayes, 2004) or attenuated cell transformation (Kuo et al., 2019).